schizophrenia

FDA Approves Noven Pharmaceuticals’ Transdermal Patch for Schizophrenia
BioSpace
Tue, 10/15/19 - 10:18 pm
Secuado
Noven Pharmaceuticals
FDA
schizophrenia
FDA cancels panel review of Intra-Cellular’s schizophrenia drug, causing shares to tumble
Stat
Tue, 07/23/19 - 07:41 pm
Intra-Cellular Therapies
FDA
advisory panels
schizophrenia
lumateperone
Acadia drops after hours on Phase III miss for schizophrenia
BioCentury
Mon, 07/22/19 - 11:08 pm
Acadia
Nuplazid
schizophrenia
clinical trials
"Smart Pill" Schizophrenia Drug Unlikely To Move Payers
Forbes
Mon, 07/22/19 - 10:03 am
Otsuka
Abilify MyCite
smart pills
schizophrenia
payers
Karuna Therapeutics Raises Its IPO Estimate to $85 Million
CP Wire
Mon, 06/17/19 - 12:22 pm
Karuna Therapeutics
IPOs
schizophrenia
Alzheimer's disease
Karuna Therapeutics Raises Its IPO Estimate to $85 Million
Mon, 06/17/19 - 09:24 am
Karuna
schizophrenia
Alzheimer's disease
Newron delays pivotal schizophrenia trials amid safety fears
Fierce Biotech
Tue, 05/28/19 - 10:34 am
Newron Pharma
clinical trials
FDA
schizophrenia
evenamide
Sunovion’s SEP-363856 gets FDA breakthrough status for schizophrenia
Pharmaceutical Business Review
Tue, 05/14/19 - 09:24 am
Sunovion
PsychoGenics
breakthrough therapies
SEP-363856
schizophrenia
Upcoming events – Acadia hopes for new indications for Nuplazid
EP Vantage
Fri, 05/3/19 - 10:18 am
Acadia Pharmaceuticals
antipsychotics
Nuplazid
schizophrenia
dementia
Schizophrenia therapy developer Karuna seeking IPO
BioCentury
Fri, 04/26/19 - 11:37 am
IPOs
Karuna
antipsychotics
schizophrenia
Luye submits NDA for schizophrenia, bipolar disorder therapy
BioCentury
Sat, 03/30/19 - 01:02 pm
Luye Pharma Group
Rykindo
schizophrenia
bipolar disorder
FDA
Karuna looks past schizophrenia with $68M series B
BioCentury
Mon, 03/18/19 - 10:37 am
Karuna
KarXT
schizophrenia
geriatric psychosis
pain
Antipsychotic from Lundbeck, Otsuka flops again in PhIII trials — this time in bipolar patients
Endpoints
Thu, 02/14/19 - 05:45 pm
Lundbeck
Otsuka
brexpiprazole
anti-psychotic
schizophrenia
bipolar disorder
Alkermes Schizophrenia Drug Heads To FDA, But Questions Linger
Xconomy
Thu, 11/29/18 - 09:37 am
ALKS-3831
Alkermes
schizophrenia
FDA
Lundbeck’s Lu AF35700 misses schizophrenia endpoint
BioCentury
Thu, 10/25/18 - 11:44 pm
Lundbeck
Lu AF35700
schizophrenia
Otsuka's dose-tracking digital pill charts its first course to market with Magellan
Fierce Pharma
Wed, 09/5/18 - 07:02 pm
Otsuka
Abilify MyCite
smart pills
digital pills
bipolar disorder
schizophrenia
Alkermes, Oklahoma negotiating value-based Medicaid purchasing agreements
BioCentury
Sun, 08/26/18 - 11:58 am
Oklahoma
Medicaid
Alkermes
Aristada
schizophrenia
Karuna raises $42M to resurrect abandoned Lilly drug for schizophrenia
Fierce Biotech
Thu, 08/2/18 - 09:56 am
Karuna Pharmaceuticals
Eli Lilly
schizophrenia
Alzheimer's disease
KarXT
xanomeline
As it fights looming competition on Suboxone, Indivior gets FDA OK on new schizophrenia drug
Endpoints
Mon, 07/30/18 - 11:24 am
Indivior
FDA
Perseris
schizophrenia
Suboxone
Biogen is hustling a schizophrenia drug into PhIIb after Pfizer lets it go in $590M CNS fire sale
Endpoints
Mon, 03/12/18 - 09:38 am
Biogen
schizophrenia
clinical trials
Pfizer
PF-04958242

Pages